Table 3. Demographic and clinicopathologic features of the 14 patients with de novo malignancy.
LT, liver transplantation; LC, liver cirrhosis; CTx, chemotherapy; HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; TACE, transhepatic arterial chemotherapy and embolization; PLC, primary liver carcinoma; RCCC, renal clear cell carcinoma; LNEC, lung neuroendocrine carcinoma; PTCD, percutaneous transhepatic cholangial drainage; ALL, acute lymphoblastic leukemia.